AMRX FY 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.0B+8.0% YoY

Gross Profit

$1.1B37.6% margin

Operating Income

$423M14.0% margin

Net Income

$72M2.4% margin

EPS (Diluted)

$0.22

Cash Flow

Operating Cash Flow

$340M

Free Cash Flow

$270M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.7B

Stockholders' Equity

-$71M

Cash & Equivalents

$311M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.0B	$2.8B	+8.0%
Gross Profit	$1.1B	$1.0B	+11.3%
Operating Income	$423M	$249M	+69.7%
Net Income	$72M	-$117M	+161.6%